By PPN News Staff
The FDA granted an expanded indication for nilotinib (Tasigna, Novartis) to include treatment of first- and second-line pediatric patients at least 12 months of age with Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase (Ph+ CML-CP).
Nilotinib is now indicated for the treatment of adults and children with newly diagnosed Ph+ CML-CP; Ph+ CML-CP resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy; and for adults with Ph+ CML